Prescription drug · NDA
Veozah (fezolinetant) NDC 0469-2760
Fezolinetant 45 mg/1 · Tablet, Film coated · Oral · Astellas Pharma US, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 0469-2760-28 | 00469276028 | 4 CARTON in 1 TRAY (0469-2760-28) / 1 BLISTER PACK in 1 CARTON (0469-2760-07) / 7 TABLET, FILM COATED in 1 BLISTER PACKMarketed from May 12, 2023 · Sample package |
How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Veozah
- Generic name (nonproprietary)
- fezolinetant
- Active ingredients
- Fezolinetant — 45 mg/1
- Dosage form
- Tablet, Film coated
- Route
- Oral
- Labeler
- Astellas Pharma US, Inc.
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 216578
- Marketing start
- Listing expires
- Other FDA classes
- Neurokinin 3 Receptor Antagonists (Mechanism)
- Identifiers
- Product ID 0469-2760_462f0a23-98d6-4154-b113-322008069743SPL ID 462f0a23-98d6-4154-b113-322008069743SPL set ID cae9f798-24f9-4580-a4fc-e6c710cbda3cRxCUI 2637141, 2637147UNII 83VNE45KXX
- Pharmacologic class
- Neurokinin 3 Receptor Antagonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N400469276028followed by a unit qualifier and the quantityPackage 00469-2760-28. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
VEOZAH ® is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause. VEOZAH is a neurokinin 3 (NK3) receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause. ( 1 )
Excerpt only. Read the full label for complete information.
Other NDCs under NDA 216578
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.